Results 151 to 160 of about 389,662 (300)

Fucoidan in cancer therapy: from biomedical application to medicinal chemistry approach. [PDF]

J Mater Sci Mater Med
Zheng Y, Fang S, Liu N, Zhang T, Huang Y, Li L, Tian Y, Hu X, Ji Y, Guo Y, Tu Y.   +10 more
europepmc   +1 more source

Bioorganic Chemistry, Medicinal Chemistry [PDF]

, 2004
井上 将彦, 藤本 和久, 阿部 肇
core   +2 more sources

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Ugi and Groebke-Blackburn-Bienaymé Reactions in Medicinal Chemistry: An Outlook on New Bioactive Compounds. [PDF]

ACS Omega
Barbosa-Reis G, Lavorenti J, Alves BL, Oliveira-Silva D.   +3 more
europepmc   +1 more source

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Lipophilic Cations as Mitochondria-Targeting Moieties: Recent Progress and Design Principles for Medicinal Chemistry. [PDF]

J Med Chem
Džajić I, Tomašič T, Pardo LA, Peterlin Mašič L, Cotman AE.   +4 more
europepmc   +1 more source

Medicinal Resources, Organomolecular Chemistry [PDF]

, 2007
矢倉 隆之
core   +1 more source

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source

Medicinal Chemistry: Abstracts 280-357

CHIMIA, 2012
doaj   +1 more source

Building a Medicinal Chemistry Framework for Bioorthogonal Probes. [PDF]

ACS Cent Sci
Staudt M, Carlson JCT.
europepmc   +1 more source